Cannabidiol (CBD) is an exciting focus of medical research, popular media, and legislation related to cannabis. Its presence is becoming ubiquitous on the shelves of health food stores and search engine results for numerous medical conditions, but don’t believe everything you hear. While CBD is an incredibly safe and therapeutic component of cannabis, there are many myths and misconceptions associated with it. Let’s take a look at a few.
Myth #1: CBD is non-psychoactive and medical; THC is recreational.
Both lay and scientific literature have classified CBD as a “non-psychoactive” substance, meaning that it does not alter one’s consciousness. But how could CBD fail to impact consciousness when it’s been shown to have anti-anxiety, anti-psychotic, anti-craving, alerting, and mood-elevating effects in human studies?
CBD clearly impacts our psyche, often in beneficial ways. It does not, however, impair mental or physical function in most consumers, even very high doses. Thus, CBD can be considered psychoactive, but “non-impairing” or “non-intoxicating.”
Continue reading “6 Common Myths and Controversies About High-CBD Cannabis”
Angela Post wasn’t supposed to study hemp. The North Carolina State agriculture researcher focuses on small grains like wheat and barley. But after the 2014 Farm Bill allowed states to investigate hemp, it became clear the seeds were lucrative. Post had the right equipment to study them, so the job was hers.
The bill legalizes the crop, allowing any farmer to grow it — whether or not they know how.
At first, Post thought hemp would get as much attention as the other alternative crops she and her colleagues dabble in. “We didn’t know how fast it would grow,” she says. Once the work garnered the attention of hundreds of would-be hemp farmers, “that’s when we got a sense it was something bigger than anticipated.”
Since then, Post’s work has expanded beyond hemp seeds — and her expertise — to fiber and flowers, which contain cannabidiol, or CBD, which is extracted for use in seizure medications and over-the-counter tinctures. But there’s no turning down hemp studies if you’re an agricultural researcher in one of the states where residents might want to grow the crop, including North Carolina, Vermont, and Kentucky.
Continue reading “The Race to Re-Learn Hemp Farming”
New Frontier Data estimates the US hemp sales will jump to $2.6 billion. Projections divide the market into CBD sales and food, fiber, fuel.
The U.S. Drug Enforcement Administration has taken some cannabidiol out of the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval.
It’s a decision that immediately affects CBD producers but also signals the agency’s first admission that the plant has medical value.
The DEA announced Thursday that drugs including CBD with THC content below 0.1% are now considered Schedule 5 drugs, as long as they have been approved by the U.S. Food and Drug Administration.
It is the first time the agency has lowered any type of cannabis from Schedule 1.
Continue reading “DEA moves some CBD medicines off Schedule 1, a limited expansion of cannabis access”
A veteran executive of both the biomass and hemp industry blasted the use of the term “biomass” by the nescient hemp industry during an interview with Cannabis Tech Media.
“Increasingly, I see companies refer to the dried hemp flowers as ‘biomass’ as they seek to buy or sell hemp bud, but the correct definition of biomass is the stalk and potentially spent bud (post extraction),” noted Ask A Hempster host Carell, also known as Carl Lehrburger. “Typically ‘biomass’ refers to non-food plant matter, including hemp and corn stalk residues, straws like wheat straw, coconut husks and seed hull, and woody biomass, which are all distinguished from the hemp flower and hemp seed, corn, and wheat kernels”, he continued.
Continue reading “What Does Hemp Biomass Actually Mean?”
2018 was the year CBD was on everyone’s lips, thanks to plenty of media buzz and the suddenly-ubiquitous presence of an array of CBD-infused beverages, lotions and self-care products. It was also the year “CBD gummies” reached No. 3 on Google’s most popular search terms. And I’m willing to go out on a limb that a significant portion of those searches were made by Baby Boomers.
Cannabidiol (CBD), a non-intoxicating compound found in cannabis, is being touted as a natural remedy for chronic pain, insomnia, depression and anxiety, among other conditions. The research to prove CBD’s therapeutic outcomes is still largely forthcoming. But even without the science, it’s no wonder that adults over 50, who suffer most from these conditions, are behind one of the fastest growing market segments for CBD products.
Continue reading “For Baby Boomers, 2018 Was The Year Of CBD. Get Ready For 2019”
This has been a transformational year for the cannabis industry, one that investors will possibly never forget. Although it’s been a bit rough on the investment front, with the Horizons Marijuana Life Sciences ETF, a basket of more than four dozen pot stocks, losing approximately 40% of its value, 2018 has been a year of gained validity for the cannabis industry.
Continue reading “Merry Christmas: Hemp and Hemp-Based CBD Are Now Legal”